A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes
Trial · NCT02692716
Adverse events840
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 840
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Abdominal pain | Gastrointestinal disorders | Oral Semaglutide | 2 | 1,591 | 2 |
| serious | Abdominal pain | Gastrointestinal disorders | Placebo | 2 | 1,591 | 2 |
| serious | Abdominal pain upper | Gastrointestinal disorders | Oral Semaglutide | 1 | 1,591 | 1 |
| serious | Abdominal pain upper | Gastrointestinal disorders | Placebo | 0 | 1,591 | 0 |
| serious | Abscess limb | Infections and infestations | Oral Semaglutide | 1 | 1,591 | 1 |
| serious | Abscess limb | Infections and infestations | Placebo | 0 | 1,591 | 0 |
| serious | Accidental overdose | Injury, poisoning and procedural complications | Oral Semaglutide | 1 | 1,591 | 1 |
| serious | Accidental overdose | Injury, poisoning and procedural complications | Placebo | 0 | 1,591 | 0 |
| serious | Acute coronary syndrome | Cardiac disorders | Oral Semaglutide | 1 | 1,591 | 1 |
| serious | Acute coronary syndrome | Cardiac disorders | Placebo | 0 | 1,591 | 0 |
| serious | Acute kidney injury | Renal and urinary disorders | Oral Semaglutide | 13 | 1,591 | 14 |
| serious | Acute kidney injury | Renal and urinary disorders | Placebo | 14 | 1,591 | 18 |
| serious | Acute left ventricular failure | Cardiac disorders | Oral Semaglutide | 2 | 1,591 | 2 |
| serious | Acute left ventricular failure | Cardiac disorders | Placebo | 2 | 1,591 | 2 |
| serious | Acute myocardial infarction | Cardiac disorders | Oral Semaglutide | 21 | 1,591 | 25 |
| serious | Acute myocardial infarction | Cardiac disorders | Placebo | 22 | 1,591 | 25 |
| serious | Acute prerenal failure | Renal and urinary disorders | Oral Semaglutide | 0 | 1,591 | 0 |
| serious | Acute prerenal failure | Renal and urinary disorders | Placebo | 1 | 1,591 | 1 |
| serious | Acute pulmonary oedema | Respiratory, thoracic and mediastinal disorders | Oral Semaglutide | 1 | 1,591 | 1 |
| serious | Acute pulmonary oedema | Respiratory, thoracic and mediastinal disorders | Placebo | 0 | 1,591 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02692716/events